Sharemaestro Newsreel

Indivior Q2 Earnings Call Highlights

Indivior and Supernus Pharmaceuticals announced an all-stock merger of equals, expected to close in Q4 2026, creating a CNS-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The combined entity will retain the Supernus name and be led by Supernus …

Trulieve Cannabis (TRLV) Could Be 51% Undervalued After Georgia Medical Cannabis Expansion

Dimensional Fund Advisors LP Has $70.53 Million Stock Position in Perrigo Company plc $PRGO

Dimensional Fund Advisors LP significantly reduced its stake in Perrigo Company plc by 11.3% in the first quarter, selling 838,228 shares, but still holds 6.57 million shares valued at approximately $70.5 million. Perrigo's recent quarterly earnings beat estimates with $0.43 EPS but revenue declined …

Axiom Investment Management LLC Takes $965,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

Axiom Investment Management LLC has acquired a new position of $965,000 in Teva Pharmaceutical Industries Ltd. during the first quarter, purchasing 32,032 shares. Institutional investors collectively own about 54.05% of the company, and analysts have a "Moderate Buy" consensus with an average target price …

Alvotech (ALVO) Is Up 34.6% After FDA Clears Reykjavik Plant And BLAs Advance - Has The Bull Case Changed?

Alvotech (ALVO) stock rose 34.6% after the FDA cleared its Reykjavik manufacturing plant with a Voluntary Action Indicated classification, addressing previous observations and allowing the company to advance multiple Biologics License Applications (BLAs) in the US. This regulatory progress, along with the acceptance of …

Journey Medical (NASDAQ:DERM) Stock Price Down 1.2% - What's Next?

Journey Medical (NASDAQ:DERM) saw its stock price decline by 1.2% to $6.37, with a significantly lower trading volume compared to its average. The company's stock is currently below its 50-day and 200-day moving averages, and analyst sentiment is mixed, resulting in a consensus "Hold" …

Canopy Growth Corp (CGC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Canopy Growth Corp (CGC), noting its current valuation score of 8.74, ranking it 44th in the Pharmaceuticals industry. It highlights the company's P/E ratio of -0.68, while stating that P/B, P/S, and P/CF data have not yet …

Tilray Brands (NASDAQ:TLRY) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen has downgraded Tilray Brands (NASDAQ:TLRY) from "Hold" to "Sell", contributing to a mixed analyst sentiment with an average "Hold" rating and an $11 price target. The company reported a significant quarterly loss of $0.43 per share, missing analyst consensus, despite revenue …

Supernus Pharmaceuticals (NASDAQ: SUPN) CEO granted 29,849 performance share units

Supernus Pharmaceuticals CEO Jack A. Khattar was granted 29,849 Performance Share Units on July 29, 2026, which correspond to one share of common stock each. These units, awarded on February 19, 2025, vested upon the achievement of individual performance objectives established on May 3, …

Access Investment Management LLC Has $456,000 Stock Holdings in Perrigo Company plc $PRGO

Access Investment Management LLC significantly reduced its stake in Perrigo Company plc (NYSE:PRGO) by 87.3% in the first quarter, now holding 42,500 shares valued at $456,000. Despite this, other institutional investors increased their positions, and analysts have a consensus "Hold" rating with an average …

Indivior PLC Lobbyists, 2023

This article from OpenSecrets details Indivior PLC's lobbying activities and lobbyists for the year 2023. It identifies 19 named lobbyists, with 15 (78.9%) having a "revolving door" background, meaning prior federal government employment. The report breaks down lobbyists by hiring firm, including Williams & …

Organigram Global Inc. Revenue Breakdown – TSX:OGI

Bausch Health Companies Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:BHC) 2026-08-01

Bausch Health Companies Inc. has published its 2026 Q2 earnings call presentation. The company reported an EPS of $1.26, beating estimates by $0.25, and revenue of $2.85 billion, surpassing expectations by $192.90 million with a 12.73% year-over-year increase. This presentation is available for investors …

Amneal (AMRX) Stock Looks About Fair Value On Current Earnings

Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

First Trust Advisors LP Acquires 116,873 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Is Liquidia (LQDA) Stock Too Rich After A 35x Run?

Elanco (ELAN) Is Up 5.9% After Credelio Quattro Outperforms Rivals in Tick Protection Study

Price to book forward of Kamada Ltd. – NASDAQ:KMDA

This page provides financial information for Kamada Ltd. (NASDAQ: KMDA), specifically focusing on its "Price to book forward" metric. The content highlights that the market was closed at the time of viewing and indicates no trades occurred. It is a financial data page from …

Talphera Inc (TLPH) Risk Assessment: Volatility, Financial Risk & Investment Risk

Talphera Inc (TLPH) has a risk assessment score of 2.24, ranking 128 out of 156 in the Pharmaceuticals industry. The stock's beta of 0.77 suggests it tends to underperform in bull markets but decline less in bear markets. The article details various risk metrics …

Teva Pharmaceutical Industries Limited Revenue Breakdown – TASE:TEVA

Teva Pharmaceutical Industries Limited reported total revenue of 53.44 billion ILS last year. The Generics, Innovative Medicines and Biopharmaceuticals segment was the top performer, contributing 59.53 billion ILS, although this was a decrease from the previous year. The United States was the largest regional …

Haleon PLC (HLN) (H1 2026) Earnings Call Highlights: Organic Growth Improves, North America ...

Haleon (NYSE: HLN) reported accelerated second-quarter organic sales growth of 3.1%, driven by strong performance in North America and emerging markets, and healthy sales in pain relief and oral health. The company maintained its full-year growth outlook of 3% to 5% and anticipates a …

United Therapeutics (UTHR) CEO trusts exercise options, sell 9,500 shares

United Therapeutics CEO Martine A. Rothblatt, through family trusts, exercised options for 9,500 shares at a strike price of $135.42 and subsequently sold all 9,500 shares in the low $520s. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, resulted in an approximate …

BioCryst Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) generated $874.84 million in revenue last year, primarily from its Oral Small-molecule and Injectable Protein Therapeutics segment. This represents a significant increase from $450.71 million in the previous year. The United States was the largest contributor to revenue, accounting …

TherapeuticsMD Inc (TXMD) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article from TradingKey provides an earnings forecast for TherapeuticsMD Inc (TXMD), focusing on future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and P/E ratio, alongside a comparison with peer companies in the pharmaceutical …

Form 4 Tilray Brands For: 31 July By Investing.com

This article provides a Form 4 filing for Tilray Brands (TLRY) for July 31. It includes the stock symbol, percentage change, and indicates the form is available for review.

SIGA Technologies (SIGA.US) will release its earnings report after market close on August 6.

SIGA Technologies (SIGA.US) is scheduled to release its earnings report on August 6, after the market closes. This announcement informs investors and stakeholders about the upcoming financial disclosure for the company.

Teva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call Presentation (NYSE:TEVA) 2026-07-31

MarketBeat Week in Review – 02/03 - 02/07 Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were largely offset by growth in its innovative medicines …

Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus

Neurocrine Biosciences (NBIX) stock dropped 10% despite strong Q2 2026 revenue and earnings, indicating the market is reacting to growth spending rather than current earnings. The company showed robust performance with INGREZZA and emerging products like CRENESSITY and VYKAT XR, but analysts are cautious …

ETFs Investing in Cumberland Pharmaceuticals Inc. Stocks

This article lists ETFs that hold Cumberland Pharmaceuticals Inc. (CPIX) stocks, providing investors with options for more accessible and lower-risk investment opportunities. It highlights one specific ETF, the Bridgeway Ultra-Small Company Market ETF (BUSM), detailing its market value, weight in CPIX, management style, and …

HUTCHMED (NASDAQ:HCM) Announces Earnings Results

Price to sales forward of Prestige Consumer Healthcare Inc. – NYSE:PBH

This article provides financial data for Prestige Consumer Healthcare Inc. (NYSE: PBH), specifically its price-to-sales forward metric. The content appears to be a financial snapshot from a trading platform, indicating market status and general financial information for the company.

Lantheus Holdings (LNTH) Pipeline Narrative Holds Firm, Does The Stock Look Fully Valued?

Lantheus Holdings (LNTH) shares recently closed at US$101, showing a strong year-to-date return of 50.14% despite a recent 9% dip. The company is considered 3% undervalued with a fair value of $104 per share, driven by an expanding radiodiagnostic pipeline including multiple new product …

Anika Therapeutics (ANIK) Stock Jumps As Profit Returns Sharpen Margin Focus

Sei Investments Co. Has $13.68 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Sei Investments Co. significantly increased its stake in Kiniksa Pharmaceuticals International (NASDAQ:KNSA) by 30.6% in the first quarter, now holding shares valued at $13.68 million. Institutional investors and hedge funds own over 53% of the company, and analysts maintain a "Buy" rating with an …